Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...

What happened with Novo Nordisk stock? On Dec. 20, Novo announced results from a phase 3 clinical trial surrounding one of ...

Novo Nordisk (NYSE: NVO) has found phenomenal success in treating patients with obesity and diabetes. Stock prices used were the afternoon prices of Jan. 1, 2025. The video was published on Jan. 3, ...

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO -1.51%) stock ...

In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...

Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of ...

Novo Nordisk retains a strong market position in a high-growth industry, with P/E multiples poised to expand. See why NVO ...

The story of Eli Lilly and Novo Nordisk’s GLP-1 dominance is likely to play out again in 2025 as the metabolic medicine ...

近年来，减肥药物市场一度成为投资者关注的焦点，随着Novo Nordisk的Wegovy和Eli ...

Novo Nordisk shares staged a dramatic rebound on Monday, recovering 8% after a steep 20% plunge on Friday. The recovery was ...

Analysts have set 12-month price targets for Novo Nordisk, revealing an average target of $145.25, a high estimate of $160.00 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...